Akeega Approval Means Three-Way PARP/Anti-Androgen Race In Prostate Cancer Is On

Despite the advantage of a single pill, the J&J drug could have the potential disadvantage of a narrower label in both the US and EU and Lynparza/Zytiga’s potentially higher efficacy.